Skip to main content

ICH Q7 Good manufacturing practice for active pharmaceutical ingredients (CPMP/ICH/4106/00)

 ICH Q7 is a guideline titled "Good Manufacturing Practice for Active Pharmaceutical Ingredients" (CPMP/ICH/4106/00). This guideline was developed to establish a harmonized approach to Good Manufacturing Practice (GMP) for the manufacturing of active pharmaceutical ingredients (APIs) across different regions of the world. Below is an elaboration of ICH Q7:


1. Purpose of ICH Q7:

The primary purpose of ICH Q7 is to provide a comprehensive framework for the GMP requirements specific to the manufacturing of APIs. The guideline ensures that APIs are consistently produced in a manner that meets quality, safety, and regulatory standards.

2. Scope:

ICH Q7 applies to the manufacturing of APIs intended for use in human pharmaceutical products. It covers the entire API manufacturing process, from starting materials to the final API.

3. Quality Management:

The guideline emphasizes the importance of establishing a robust quality management system to oversee API manufacturing. This includes quality risk management, quality assurance, and quality control.

4. Documentation and Record Keeping:

Comprehensive documentation and record-keeping systems are essential. Detailed records should be maintained for all stages of API manufacturing, including raw material control, production, testing, and distribution.

5. Personnel:

ICH Q7 outlines the qualifications and training requirements for personnel involved in API manufacturing. Personnel should be trained to perform their tasks effectively and safely.

6. Facilities and Equipment:

The guideline specifies requirements for facilities and equipment used in API manufacturing. Facilities should be designed, maintained, and operated to prevent contamination, cross-contamination, and mix-ups.

7. Process Validation:

Process validation is a critical component of API manufacturing. Manufacturers should validate and document the processes used to produce APIs, demonstrating their consistency and reliability.

8. Change Control:

Procedures for change control are essential to ensure that any changes in API manufacturing processes, equipment, or materials are properly evaluated, documented, and validated.

9. Starting Materials:

The guideline emphasizes the importance of selecting and controlling starting materials carefully. Manufacturers should ensure the quality and traceability of starting materials.

10. Specifications and Testing:

- Detailed specifications for APIs should be established, including criteria for identity, purity, potency, and other critical quality attributes. Appropriate analytical methods should be used to test APIs.

11. Cleaning and Cross-Contamination:

- Measures should be in place to prevent cross-contamination between different APIs or products. Cleaning procedures should be validated to ensure the removal of residues.

12. Packaging and Labeling:

- ICH Q7 includes requirements for the packaging and labeling of APIs. These processes should be carried out in a way that maintains the integrity of the API.

13. Complaints and Recalls:

- Procedures for handling complaints and initiating recalls of APIs should be established and documented.

14. Regulatory Compliance:

- Compliance with ICH Q7 is typically required by regulatory authorities when manufacturing APIs. Manufacturers must adhere to these guidelines to ensure the quality and safety of APIs.


In summary, ICH Q7 provides a comprehensive framework for GMP specific to the manufacturing of active pharmaceutical ingredients (APIs). Compliance with these guidelines is essential to ensure the quality, safety, and consistency of APIs used in pharmaceutical products. The guideline helps harmonize GMP standards globally, facilitating international trade and regulatory cooperation in the pharmaceutical industry

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

Guideline on development and manufacture of lentiviral vectors (CHMP/BWP/2458/03)

The guideline with the reference number "CHMP/BWP/2458/03" pertains to the "Guideline on Development and Manufacture of Lentiviral Vectors." This guideline was developed by the Committee for Medicinal Products for Human Use (CHMP) and the Biotechnology Working Party (BWP) of the European Medicines Agency (EMA). It provides recommendations and regulatory guidance for the development and manufacture of lentiviral vectors, which are widely used in gene therapy and cell therapy applications. Here's an overview of the key points covered in this guideline: 1. Introduction: The guideline begins with an introduction highlighting the increasing importance of lentiviral vectors in advanced therapies and the need for guidance on their development and manufacture. 2. Scope: It defines the scope of the guideline, which covers the development and manufacture of lentiviral vectors intended for use in gene therapy and cell therapy products for human use. 3. Quality and Characte...
Read more

ICH Q5D Derivation and characterisation of cell substrates used for production of biotechnological/biological products (CPMP/ICH/294/95)

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines to ensure the quality, safety, and efficacy of pharmaceutical products. ICH Q5D, as outlined in document CPMP/ICH/294/95, addresses the derivation and characterization of cell substrates used for the production of biotechnological and biological products. Below is a detailed elaboration of ICH Q5D: 1. Purpose of ICH Q5D: ICH Q5D provides guidelines for the establishment of cell substrates used in the production of biotechnological and biological products. The primary goal is to ensure the quality, safety, and consistency of cell substrates to minimize potential risks associated with the final product. 2. Cell Substrate Characterization: The guideline emphasizes the importance of thorough characterization of the cell substrate. This includes the origin of the cells, their history, and any relevant genetic information. Detailed documentation of the cell line...
Read more

ICH E3 Structure and content of clinical study reports (CPMP/ICH/137/95)

 The ICH E3 guideline, titled "Structure and Content of Clinical Study Reports," with the reference number CPMP/ICH/137/95, provides recommendations and a standardized framework for the structure and content of clinical study reports (CSRs). CSRs are essential documents that summarize the results and findings of clinical trials conducted during the drug development process. Here's an elaboration of ICH E3: 1. Purpose: The primary purpose of ICH E3 is to provide guidance on the organization, content, and format of CSRs to ensure consistency and clarity in reporting clinical trial data. It aims to facilitate the evaluation of the safety and efficacy of investigational drugs by regulatory authorities. 2. Applicability: ICH E3 is applicable to CSRs for all phases of clinical trials, including Phase I, II, III, and post-marketing studies. 3. Structure of the CSR: The guideline outlines a standardized structure for the CSR, which typically includes the following sections: Title...
Read more

ICH 5QC Stability testing of biotechnological/biological products (CPMP/ICH/138/95)

ICH Topic Q5C, as outlined in document CPMP/ICH/138/95, addresses the stability testing of biotechnological and biological products. This guideline provides a framework for assessing the stability of these products over time, ensuring that they maintain their quality, safety, and efficacy throughout their shelf life. Below is an elaboration of ICH Q5C: 1. Purpose of ICH Q5C: The primary purpose of ICH Q5C is to establish principles and guidelines for conducting stability testing of biotechnological and biological products. The goal is to provide evidence that these products remain safe and effective during their intended shelf life. 2. Types of Products Covered: ICH Q5C applies to a wide range of biotechnological and biological products, including monoclonal antibodies, recombinant proteins, vaccines, gene therapies, and other biopharmaceuticals. 3. Stability Study Design: The guideline outlines the design of stability studies, including the selection of relevant storage conditions, ti...
Read more